A UK biotech looks to bring al­liance be­tween GSK, J&J, As­traZeneca, and top uni­ver­si­ties state­side with its first megaround

Richard Ma­son was work­ing at the J&J In­no­va­tion Cen­ter in Lon­don about six years ago when the com­pa­ny linked arms with two oth­er phar­mas and three of the UK’s lead­ing uni­ver­si­ties to form Apol­lo Ther­a­peu­tics — a trans­la­tion­al med­i­cine group aimed at spin­ning out new ther­a­pies. Now he’s run­ning the show at Apol­lo, and he’s pulled in $145 mil­lion to dri­ve those pro­grams in­to the clin­ic.

Ma­son un­veiled what he calls Apol­lo’s “first in­sti­tu­tion­al fi­nanc­ing” ear­ly Thurs­day morn­ing, which he plans on us­ing to beef up op­er­a­tions both in the UK and the US, and ad­vance a port­fo­lio of more than 15 pro­grams.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER